We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mammography Screening Intervals May Affect Breast Cancer Prognosis

By HospiMedica International staff writers
Posted on 02 Jan 2014
In a study of screening mammography-detected breast tumors, patients who had more frequent screening mammography exams had a considerably lower rate of lymph node positivity as compared to women who had longer intervals between screening-mammography exams. More...


The study’s findings were presented December 3, 2013, at the annual meeting of the Radiological Society of North America (RSNA), held December 2013 in Chicago (IL, USA). In its earliest stages, breast cancer is confined to the breast and can be treated by surgically removing the cancer cells. Breast cancer cells may metastasize to the lymph nodes as the disease progresses and then to other areas of the body.

“On its pathway to other places in the body, the first place breast cancer typically drains into before metastasizing is the lymph nodes,” said Lilian Wang, MD, assistant professor of radiology at Northwestern University/Feinberg School of Medicine (Chicago, IL, USA). “When breast cancer has spread into the lymph nodes, the patient is often treated both locally and systemically, with either hormone therapy, chemotherapy, trastuzumab, or some combination of these therapies.”

Healthcare organizations, such as RSNA and the American Cancer Society (ACS), have recommended yearly screening with mammography for women beginning at age 40. However, in 2009, the United States Preventive Services Task Force (USPSTF) announced a controversial new recommendation for biennial screening for women between the ages of 50 and 74. “Our study looks at what would happen if the revised guidelines issued by USPSTF were followed by women,” Dr. Wang said.

Conducted at Northwestern Memorial Hospital (Chicago, IL, USA), the retrospective study, included 332 women with breast cancer identified by screening mammography between 2007 and 2010. The women were split into one of three groups, based on the length of time between their screening mammography exams: less than 1.5 years, 1.5 to three years, and more than three years. There were 207, 73, and 52 patients in each category, respectively.

The researchers determined, controlling for age, breast density, high-risk status, and a family history of breast cancer, that women in the less than 1.5-year interval group had the lowest lymph node positivity rate at 8.7%. The rate of lymph node involvement was substantially higher in the 1.5- to three-year and over three-year interval groups at 20.5% and 15.4%, respectively.

“Our study shows that screening mammography performed at an interval of less than 1.5 years reduces the rate of lymph node positivity, thereby improving patient prognosis,” Dr. Wang concluded. “We should be following the guidelines of the American Cancer Society and other organizations, recommending that women undergo annual screening mammography beginning at age 40.”

Related Links:

Northwestern University/Feinberg School of Medicine




Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Fetal Monitor
BT-380
Pediatric Mask
Respire SOFT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Sphere-9 is the first all-in-one mapping and ablation, large-tip focal, dual-energy catheter to be CE marked for ventricular ablation (Photo courtesy of Medtronic)

Dual-Energy Mapping and Ablation Catheter Receives CE Mark for Ventricular Arrhythmias

Ventricular arrhythmias, including ventricular tachycardia and premature ventricular complexes, can be life-threatening and often occur in patients with advanced heart disease. Although catheter ablation... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.